Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Kamlesh K. Bhopale, Mukund P. Srinivasan

Research output: Contribution to journalReview articlepeer-review


Metabolic dysfunction associated fatty liver disease (MAFLD) has been recently recognized as a new global chronic liver disease entity with non-alcoholic fatty liver disease (NAFLD) associated with overweight/obesity or type 2 diabetes mellitus (T2DM) and evidence of metabolic dysregulation. Due to the rising rates of obesity and diabetes, MAFLD is considered a rapidly emerging chronic liver disease globally. Nearly 25–30% of the global population poses health issues due to MAFLD with a substantial economic burden to societies. Disease progression depends on the persistence of risk factors and etiological agents, from simple steatosis, hepatitis, fibrosis, to cirrhosis, and if untreated, leads to hepatocellular carcinoma. In this review article we summarize various risk and etiological factors, diagnostic techniques, and therapeutic evaluation of pharmacological agents developed for MAFLD. Effective pharmaceutical agents for the treatment of MAFLD (and NAFLD) are lacking, and research is ongoing to search for effective medications in this direction. Currently, pioglitazone is advised for MAFLD patients, whereas Vitamin E is advised for non-diabetic MAFLD patients with ≥F2 non-cirrhosis. Current approaches to disease management emphasize diet control, lifestyle changes, and weight loss. In this review, we summarized the pharmacological agents currently being developed and their current status to treat patients with MAFLD.

Original languageEnglish (US)
Pages (from-to)597-617
Number of pages21
Issue number4
StatePublished - Dec 2023
Externally publishedYes


  • metabolic disorder
  • metabolic dysfunction
  • metabolic dysfunction-associated fatty liver disease( MAFLD)
  • non-alcoholic fatty liver disease (NAFLD)
  • pharmacological agents
  • therapeutics

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)'. Together they form a unique fingerprint.

Cite this